<DOC>
	<DOC>NCT02568423</DOC>
	<brief_summary>The main purpose of this study is to explore the safety and tolerability of LY3074828 in healthy Japanese and Caucasian participants. The study will also estimate how much LY3074828 gets into the blood stream and how long it takes the body to remove it. The study is expected to last about 16 weeks for each participant.</brief_summary>
	<brief_title>A Study of LY3074828 in Healthy Participants</brief_title>
	<detailed_description />
	<criteria>Are overtly healthy males or females, as determined by medical history and physical examination. Are first generation Japanese or are Caucasian. Have a body mass index (BMI) of 18.0 kilograms per square meter (kg/m2) to 32.0 kg/m2, inclusive, at screening. Have a body weight of 40.0 kg or higher for Cohorts 1, 2, 3 and 4, and 48.0 kg or higher for Cohort 5. Have had symptomatic herpes zoster within 3 months of screening. Show evidence of active or latent tuberculosis (TB), as documented by medical history and examination, chest xrays (posterior anterior and lateral), and TB testing. Have received live vaccine(s) within 1 month of screening or intend to during the study. Are immunocompromised. Have received treatment with biologic agents (such as monoclonal antibodies, including marketed drugs) within 3 months or 5 halflives (whichever is longer) prior to dosing.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>